Pharmacokinetic modeling of doxorubicin pharmacokinetics in dogs deficient in ABCB1 drug transporters

Journal of Veterinary Internal Medicine

Volumn 24, Issue 3, 2010, Pages 579-586

  Gustafson, D L ^a   Thamm, D H ^a  

^a Department of Environmental and Radiological Health Sciences   (United States)

Author keywords

Chemotherapy; Monte Carlo simulation; PBPK modeling; Polymorphisms

Indexed keywords

ANTINEOPLASTIC AGENT; DOXORUBICIN; ORGANIC ANION TRANSPORTER;

ANIMAL; ANIMAL DISEASE; ARTICLE; BIOLOGICAL MODEL; BLOOD; COMPUTER SIMULATION; DOG; GENETICS; HOMOZYGOTE; METABOLISM; MONTE CARLO METHOD; NEOPLASM;

ANIMALS; ANTINEOPLASTIC AGENTS; COMPUTER SIMULATION; DOGS; DOXORUBICIN; HOMOZYGOTE; MODELS, BIOLOGICAL; MONTE CARLO METHOD; NEOPLASMS; ORGANIC ANION TRANSPORTERS;

ANIMALIA; CANIS FAMILIARIS;

EID: 77954371576     PISSN: 08916640     EISSN: 19391676     Source Type: Journal    
DOI: 10.1111/j.1939-1676.2010.0496.x     Document Type: Article

References (37)

1. Zunino F, Gambetta R, Di Marco A. The inhibition in vitro of DNA polymerase and RNA polymerase by daunomycin and adriamycin. Biochem Pharmacol 1975, 24:309-311.
2. Tewey KM, Chen GI, Nelson EM. Intercalative anti-tumor drugs interfere with the breakage-reunion reaction of mammalian DNA topoisomerase. J Biol Chem 1984, 259:9182-9187.
3. Taatjes DJ, Gaudiano G, Resing K. Alkylation of DNA by the anthracycline, antitumor drugs adriamycin and daunomycin. J Med Chem 1996, 39:4135-4138.
4. Doroshow JH. Role of hydrogen peroxide and hydroxyl radical in the killing of Ehrlich tumor cells by anticancer quinones. Proc Natl Acad Sci USA 1985, 83:4514-4518.
5. Bachur NR, Gordon SL, Gee MV. A general mechanism for microsomal activation of quinone anticancer agents to free radicals. Cancer Res 1978, 38:1745-1750.
6. Pessah IN, Durie EL, Schiedt MJ. Anthraquinone-sensitized Ca2+ release channel from rat cardiac sarcoplasmic reticulum: Possible receptor-mediated mechanism of doxorubicin cardiomyopathy. Mol Pharmacol 1990, 37:503-514.
7. Oakes SG, Schlager JJ, Santone KS. Doxorubicin blocks the increase in intracellular Ca++, part of a second messenger system in N1E-115 murine neuroblastoma cells. J Pharmacol Exp Therap 1990, 252:979-983.
8. Mau BL, Powis G. Inhibition of cellular thioredoxin reductase by diaziquone and doxorubicin: Relationship to the inhibition of cell proliferation and decreased ribonucleotide reductase activity. Biochem Pharmacol 1992, 43:1621-1626.
9. Morré DJ, Kim C, Paulik M. Is the drug-responsive NADH oxidase of the cancer cell plasma membrane a molecular target for Adriamycin? J Bioener Biomemb 1997, 29:269-280.
10. Young RC, Ozols RF, Myers CE. The anthracycline neoplastic drugs. N Engl J Med 1981, 305:139-153.
11. Terasaki T, Iga T, Sugiyama Y. Experimental evidence of characteristic tissue distribution of Adriamycin: Tissue DNA concentration as a determinant. J Pharm Pharmacol 1982, 34:597-600.
12. Nicolay K, Timmers RJM, Spoelstra E. The interaction of adriamycin with cardiolipin in model and rat liver mitochondrial membranes. Biochim Biophys Acta 1984, 778:359-371.
13. Goormaghtigh E, Chatelain P, Caspers J. Evidence of a specific complex between adriamycin and negatively-charged phospholipids. Biochim Biophys Acta 1980, 597:1-14.
14. Gustafson DL, Rastatter JC, Colombo T. Doxorubicin pharmacokinetics: Macromolecule binding, metabolism and elimination in the context of a physiological model. J Pharm Sci 2002, 91:1488-1501.
15. van Asperen J, van Tellingen O, Beijnen JH. The role of mdr1a p-glycoprotein in the biliary and intestinal secretion of doxorubicin and vinblastine in mice. Drug Metab Dispos 2000, 28:264-267.
16. Roulet A, Puel O, Gesta S. MDR1-deficient genotype in Collie dogs hypersensitive to the P-glycoprotein substrate ivermectin. Eur J Pharmacol 2003, 460:85-91.
17. Hugnet C, Bentjen SA, Mealey KL. Frequency of the mutant MDR1 allele associated with multidrug sensitivity in a sample of Collies from France. J Vet Pharmacol Ther 2004, 27:227-229.
18. Mealey KL. Therapeutic implications of the MDR-1 gene. J Vet Pharmacol Ther 2004, 27:257-264.
19. Mealey KL, Munyard KA, Bentjen SA. Frequency of the mutant MDR1 allele associated with multidrug sensitivity in a sample of herding breed dogs living in Australia. Vet Parasitol 2005, 131:193-196.
20. Mealey KL, Northrup NC, Bentjen SA. Increased toxicity of P-glycoprotein-substrate chemotherapeutic agents in a dog with the MDR1 deletion mutation associated with ivermectin sensitivity. J Am Vet Med Assoc 2003, 223:1453-1455. 1434
21. Neff MW, Robertson KR, Wong AK. Breed distribution and history of canine mdr1-1-Delta, a pharmacogenetic mutation that marks the emergence of breeds from the collie lineage. Proc Natl Acad Sci USA 2004, 101:11725-11730.
22. Mealey KL, Fidel J, Gay JM. ABCB1-1-Delta polymorphism can predict hematologic toxicity in dogs treated with vincristine. J Vet Intern Med 2008, 22:996-1000.
23. Brown RP, Delp MD, Lindstedt SL. Physiological parameter values for physiologically based pharmacokinetic models. Toxicol Ind Health 1997, 13:407-484.
24. Lahtinen R, Lahtinen T, Romppanen T. Bone and bone-marrow blood flow in chronic granulocytic leukemia and primary myelofibrosis. J Nucl Med 1982, 23:218-224.
25. Loveless H, Arena E, Felsted RL. Comparative mammalian metabolism of adriamycin and daunorubicin. Cancer Res 1978, 38:593-598.
26. Thomas RS, Lytle WE, Keefe TJ. Incorporating monte carlo simulation into physiologically based pharmacokinetic models using advanced continuous simulation language (ACSL): A computational method. Fund Appl Toxicol 1996, 31:19-28.
27. Thomas RS, Bigelow PL, Keefe TJ. Variability in biological exposure indices using physiologically based pharmacokinetic modeling and monte carlo simulation. Am Ind Hyg Assoc J 1996, 57:23-32.
28. Portier CJ, Kaplan NL. Variability of safe dose estimates when using complicated models of the carcinogenic process. Fundam Appl Toxicol 1989, 13:533-544.
29. Naylor T, Balinty J, Burdick D. Computer Simulation Techniques 1968, New York, Wiley
30. Selting KA, Ogilvie GK, Gustafson DL. Evaluation of the effects of dietary n-3 fatty acid supplementation on the pharmacokinetics of doxorubicin in dogs with lymphoma. Am J Vet Res 2006, 67:145-151.
31. Harris PA, Garai AS, Valenzuela MA. Reduction of doxorubicin (adriamycin) bone marrow toxicity. J Pharm Sci 1975, 64:1574-1576.
32. Mealey KL, Bentjen SA, Waiting DK. Frequency of the mutant MDR1 allele associated with ivermectin sensitivity in a sample population of Collies from the northwestern United States. Am J Vet Res 2002, 63:479-481.
33. van Asperen J, van Tellingen O, Tijssen F. Increased accumulation of doxorubicin and doxirubicinol in cardiac tissue of mice lacking mdr1a P-glycoprotein. Br J Cancer 1999, 79:108-113.
34. Colombo T, Zucchetti M, D'Incalci M. Cyclosporin A markedly changes the distribution of doxorubicin in mice and rats. J Pharmacol Exp Therap 1994, 269:22-27.
35. Colombo T, Gonzalez Paz O, D'Incalci M. Distribution and activity of doxorubicin combined with SDZ PSC 833 in mice with P388 and P388/DOX leukaemia. Br J Cancer 1996, 73:866-871.
36. Price PS, Conolly RB, Chaisson CF. Modeling interindividual variation in physiological factors used in PBPK models of humans. Crit Rev Toxicol 2003, 33:469-503.
37. Gustafson DL, Long ME. Alterations in P-glycoprotein expression in mouse tissues by doxorubicin: Implications for pharmacokinetics in multiple dosing regimens. Chem Biol Int 2001, 138:43-57.